Literature DB >> 23370861

KIR gene variability in cutaneous malignant melanoma: influence of KIR2D/HLA-C pairings on disease susceptibility and prognosis.

José A Campillo1, Isabel Legaz, M Rocío López-Álvarez, José Miguel Bolarín, Beatriz Las Heras, Manuel Muro, Alfredo Minguela, María R Moya-Quiles, Rosa Blanco-García, Helios Martínez-Banaclocha, Ana M García-Alonso, M Rocío Alvarez-López, Jorge A Martínez-Escribano.   

Abstract

Natural killer and CD8(+) T cells are believed to be involved in the immune protection against melanoma. Their function may be regulated by a group of receptors defined as killer immunoglobulin-like receptors (KIRs) and their cognate HLA class I ligands. In this study, we analyzed the influence of KIR genes and KIR/HLA-I combinations on melanoma susceptibility and/or prognosis in a Spanish Caucasian population. For this purpose, KIR genotyping by PCR-SSP and HLA-C genotyping by reverse PCR-SSO were performed in 187 melanoma patients and 200 matched controls. We found a significantly low frequency of KIR2DL3 in nodular melanoma (NM) patients (P = 0.001) and in ulcerated melanoma patients (P < 0.0001). Similarly, the KIR2DL3/C1 combination was significantly decreased in melanoma patients (Pc = 0.008) and in patients with sentinel lymph node (SLN) melanoma metastasis (Pc = 0.002). Multivariate logistic regression models showed that KIR2DL3 behaves as a protective marker for NM and ulcerated melanoma (P = 0.02, odds ratio (OR) = 0.14 and P = 0.04, OR = 0.28, respectively), whereas the KIR2DL3/C1 pair acts as a protective marker for melanoma (P = 0.017, OR = 0.54), particularly superficial spreading melanoma (P = 0.02, OR = 0.52), and SLN metastasis (P = 0.0004, OR = 0.14). In contrast, the KIR2DL3(-)/C1C2 genotype seems to be correlated with NM and ulceration. We also report that the KIR2DL1(+)/S1(-)/C2C2 genotype is associated with susceptibility to melanoma and SLN metastasis. Altogether, the study of KIR2D genes and HLA-C ligands may help in assessing cutaneous melanoma risk and prognosis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23370861     DOI: 10.1007/s00251-013-0682-0

Source DB:  PubMed          Journal:  Immunogenetics        ISSN: 0093-7711            Impact factor:   2.846


  49 in total

Review 1.  MHC class I molecules and KIRs in human history, health and survival.

Authors:  Peter Parham
Journal:  Nat Rev Immunol       Date:  2005-03       Impact factor: 53.106

Review 2.  Surface NK receptors and their ligands on tumor cells.

Authors:  Lorenzo Moretta; Cristina Bottino; Daniela Pende; Roberta Castriconi; Maria Cristina Mingari; Alessandro Moretta
Journal:  Semin Immunol       Date:  2006-05-26       Impact factor: 11.130

Review 3.  Expression of adhesion molecules and ligands for activating and costimulatory receptors involved in cell-mediated cytotoxicity in a large panel of human melanoma cell lines.

Authors:  Javier G Casado; Graham Pawelec; Sara Morgado; Beatriz Sanchez-Correa; Elena Delgado; Inmaculada Gayoso; Esther Duran; Rafael Solana; Raquel Tarazona
Journal:  Cancer Immunol Immunother       Date:  2009-03-04       Impact factor: 6.968

4.  HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1.

Authors:  Jeffrey M Venstrom; Gianfranco Pittari; Ted A Gooley; Joseph H Chewning; Stephen Spellman; Michael Haagenson; Meighan M Gallagher; Mari Malkki; Effie Petersdorf; Bo Dupont; Katharine C Hsu
Journal:  N Engl J Med       Date:  2012-08-30       Impact factor: 91.245

5.  HLA-Cw group 1 ligands for KIR increase susceptibility to invasive cervical cancer.

Authors:  Maureen P Martin; Ingrid B Borecki; Zhengyan Zhang; Loan Nguyen; Duanduan Ma; Xiaojiang Gao; Ying Qi; Mary Carrington; Janet S Rader
Journal:  Immunogenetics       Date:  2010-09-21       Impact factor: 2.846

6.  Susceptibility of human melanoma cells to autologous natural killer (NK) cell killing: HLA-related effector mechanisms and role of unlicensed NK cells.

Authors:  Paolo Carrega; Gaetana Pezzino; Paola Queirolo; Irene Bonaccorsi; Michela Falco; Giuseppe Vita; Daniela Pende; Aldo Misefari; Alessandro Moretta; Maria Cristina Mingari; Lorenzo Moretta; Guido Ferlazzo
Journal:  PLoS One       Date:  2009-12-04       Impact factor: 3.240

Review 7.  The paradox of T-cell-mediated antitumor immunity in spite of poor clinical outcome in human melanoma.

Authors:  Andrea Anichini; Claudia Vegetti; Roberta Mortarini
Journal:  Cancer Immunol Immunother       Date:  2004-06-03       Impact factor: 6.968

8.  Role of the inhibitory KIR ligand HLA-Bw4 and HLA-C expression levels in the recognition of leukemic cells by Natural Killer cells.

Authors:  Sonja Verheyden; Soldano Ferrone; Arend Mulder; Frans H Claas; Rik Schots; Barbara De Moerloose; Yves Benoit; Christian Demanet
Journal:  Cancer Immunol Immunother       Date:  2008-10-08       Impact factor: 6.968

9.  Protection from lysis by natural killer cells of group 1 and 2 specificity is mediated by residue 80 in human histocompatibility leukocyte antigen C alleles and also occurs with empty major histocompatibility complex molecules.

Authors:  O Mandelboim; H T Reyburn; M Valés-Gómez; L Pazmany; M Colonna; G Borsellino; J L Strominger
Journal:  J Exp Med       Date:  1996-09-01       Impact factor: 14.307

10.  Biosynthesis of HLA-C heavy chains in melanoma cells with multiple defects in the expression of HLA-A, -B, -C molecules.

Authors:  A Martayan; R Fraioli; E Giorda; A Setini; G Ciccarelli; L Delfino; G B Ferrara; P Giacomini
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

View more
  6 in total

Review 1.  KIR and HLA under pressure: evidences of coevolution across worldwide populations.

Authors:  Danillo G Augusto; Maria Luiza Petzl-Erler
Journal:  Hum Genet       Date:  2015-06-23       Impact factor: 4.132

2.  Association of killer cell immunoglobulin-like receptor gene 2DL1 and its HLA-C2 ligand with family history of cancer in oral squamous cell carcinoma.

Authors:  Anupam Dutta; Nabajyoti Saikia; Jyotirmoy Phookan; Munindra Narayan Baruah; Shashi Baruah
Journal:  Immunogenetics       Date:  2014-05-13       Impact factor: 2.846

3.  Skin Cancer Risk Is Modified by KIR/HLA Interactions That Influence the Activation of Natural Killer Immune Cells.

Authors:  Karin A Vineretsky; Margaret R Karagas; Brock C Christensen; Jacquelyn K Kuriger-Laber; Ann E Perry; Craig A Storm; Heather H Nelson
Journal:  Cancer Res       Date:  2016-01-07       Impact factor: 12.701

4.  KIR-HLA gene diversities and susceptibility to lung cancer.

Authors:  Marjan Hematian Larki; Elham Ashouri; Shaghik Barani; Seiyed Mohammad Ali Ghayumi; Abbas Ghaderi; Raja Rajalingam
Journal:  Sci Rep       Date:  2022-10-14       Impact factor: 4.996

5.  Characterization of the Microenvironment in Positive and Negative Sentinel Lymph Nodes from Melanoma Patients.

Authors:  Meriem Messaoudene; Aurélie Périer; Giulia Fregni; Emmanuelle Neves; Laurence Zitvogel; Isabelle Cremer; Johan Chanal; Xavier Sastre-Garau; Lydia Deschamps; Eduardo Marinho; Frederique Larousserie; Eve Maubec; Marie-Françoise Avril; Anne Caignard
Journal:  PLoS One       Date:  2015-07-28       Impact factor: 3.240

6.  Analysis of Killer Cell Immunoglobulin-Like Receptor Genes and Their HLA Ligands in Inflammatory Bowel Diseases.

Authors:  Fereshteh Beigmohammadi; Mahdi Mahmoudi; Jafar Karami; Nooshin Ahmadzadeh; Nasser Ebrahimi-Daryani; Nima Rezaei
Journal:  J Immunol Res       Date:  2020-09-19       Impact factor: 4.818

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.